Covid-19 CD40 RBDv is under clinical development by LinKinVax Europe Spas and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

Zofin is under clinical development by ZEO ScientifiX and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome.

Not Disclosed Neuroscience and Pain 2 is under clinical development by Evotec and currently in Phase I for Unspecified Neurologic Disorders.

GIP/GLP-1 Coagonist III is under clinical development by Eli Lilly and Co and currently in Phase I for Cardiometabolic Disease.

CYTO-102 is under clinical development by CytoImmune Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer.

QL-401 is under clinical development by QLSF Biotherapeutics and currently in Phase I for Peripheral T-Cell Lymphomas (PTCL).

PrimePro is under clinical development by Thomas Advanced Medical and currently in Phase I for Coronavirus Disease 2019 (COVID-19).

Sodium calcium edetate + tobramycin is under clinical development by Respirion Pharmaceuticals and currently in Phase II for Cystic Fibrosis.

Anti-PD-1/VEGF BsAb is under clinical development by 3SBio and currently in Phase II for Gynecological Cancer.

R3R-01 is under development for the treatment of Alport syndrome, diabetic kidney disease and focal segmental glomerulosclerosis. It is administered through oral route.

IMM-1-104 is under clinical development by Immuneering and currently in Phase II for Non-Small Cell Lung Cancer.

HB-adMSC Allogeneic is under clinical development by Hope Biosciences and currently in Phase II for Coronavirus Disease 2019 (COVID-19).